Choose language

en
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

English
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Pfizer

PFE.US $ 45.34 USD

-0.56 $ (-1.22%)

Growth potential

Recommendation
is being revised

Dividend income

4.07%

1d
1w
1mo
6mths
All the time

Add to cart

1 lot = 1 stock

Purchase amount:

Brokerage commission:

Transfer commission:

Recommendation

Strong Buy

Performance Rating

DCF

40.34

ROE

0.15

ROA

0.06

P/S

4.76

P/B

3.16

Debt / Equity

0.56

About Company

An American corporation Pfizer Inc. specializes in manufacturing pharmaceutical drugs, such as Diflucan, Celebrex, Viagra. The company is almost 170 years old, and its growth peak was at the end of the 20th century when new and highly efficient results of "Pfizer" developments entered the market. The beginning of the 19th century was the time of mergers and acquisitions with the largest one being with an Irish company Allergan. Up to now, the company's existence was based on several successful developments; however, in future, it aims at abandoning this strategy and start investing in biotechnologies, for which purpose it purchased Wyeth company. A special attention will be paid to biological drugs of natural origin that slow aging. According to statistics, Pfizer accounts for more than 6% of the global drug market - the company is the leader of its sector. The company capitalization amounts to $190 billion; in 2017, the net profit amounted to $13.7 billion with annual turnover facing a slight decrease. Earlier, the stocks had been falling in price for several years, probably, due to a prolonged reorganization of the company; however, since 2016, an upward trend has become visible. As far as the further destiny of the Pfizer stocks is concerned, analysts stick to moderately optimistic opinion connected with a clear viewpoint of Ian Read who became the President of the company in 2010. His whole career has been dedicated to Pfizer; he got the highest position on the back of reorganization, has completed it and returned the company back to high financial results.


Sign up for investment ideas from Freedom Finance analysts

We will send an e-mail once a week containing only the most relevant and important information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in